HDG8 Antibody
Description
Introduction to HD8 Antibody
HD8 is a fully human IgG2κ monoclonal antibody generated using transchromosome mice engineered with human immunoglobulin genes . It exhibits broad reactivity against HLA-DR alleles, making it a candidate for immunotherapy targeting B-cell malignancies .
Antibody Generation and Validation
HD8 was developed by immunizing transchromosome mice with HLA-DR-transfected L929 cells. Hybridomas were screened for reactivity, leading to the selection of HD8 due to its pan-HLA-DR specificity . Key validation steps included:
-
Binding assays: HD8 recognized 100% of HLA-DR-positive cell lines (n = 13) and B-cells from healthy donors (n = 35) .
-
Epitope mapping: HD8 targets the polymorphic region of the HLA-DRB chain, with critical residues conserved across >99% of HLA-DR alleles .
Mechanisms of Action
HD8 exerts antitumor effects via two primary mechanisms:
-
Antibody-dependent cellular cytotoxicity (ADCC): HD8 recruits natural killer (NK) cells to eliminate HLA-DR-expressing tumors .
-
Complement-dependent cytotoxicity (CDC): HD8 activates the complement cascade, inducing direct tumor lysis .
In Vitro and In Vivo Efficacy
| Parameter | Result | Source |
|---|---|---|
| ADCC activity (EC₅₀) | 0.5–2.0 μg/mL | |
| CDC activity (EC₅₀) | 0.1–0.5 μg/mL | |
| Survival extension in NHL mice | Significant lifespan increase (vs. control) |
Cross-Reactivity with HLA Alleles
HD8 demonstrates remarkable cross-reactivity:
| HLA Class | Allele Coverage | Key Epitope Conservation |
|---|---|---|
| HLA-DR | 99.2% | Polymorphic residues in HLA-DRB chain |
| HLA-DP | 100% | Partial conservation of HD8-binding residues |
| HLA-DQ | 66% | Limited conservation |
Therapeutic Applications
HD8 is under investigation for B-cell malignancies (e.g., non-Hodgkin lymphoma) due to its:
-
Broad reactivity: Targets diverse HLA-DR-expressing tumors .
-
Low immunogenicity: Fully human structure minimizes anti-drug antibody risk .
-
Synergy with existing therapies: Combines with rituximab (anti-CD20) for enhanced cytotoxicity .
Research Limitations and Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
